alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 1–25 of 29 studies in Brain scans and imaging published 2006 (page 1 of 2) · 27,380 in the whole library · How the 0–100 score works

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Other subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 12,859 studies have no institution on record and are not counted here.

What “Brain scans and imaging” covers

Brain scans and imaging — MRI, PET and other scans: what they show, how early, and how reliably.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

[11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease

✓ Peer-reviewed alzhub usefulness score 66 out of 100. Neurology 2006-08-01

Longitudinal studies will be required to determine the association of elevated [(11)C]PIB binding and risk of developing dementia of the Alzheimer type. 2 key findings →

Design: longitudinal study Evidence: moderate

Full summary, score breakdown and related studies → Original source Full text may need a subscription

An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest

✓ Peer-reviewed alzhub usefulness score 61 out of 100. NeuroImage 2006-03-14

In this study, researchers assessed the validity and reliability of an automated labeling system developed to subdivide the human cerebral cortex on magnetic resonance images into gyral based regions of interest. 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Thyroid hormones, dementia, and atrophy of the medial temporal lobe

✓ Peer-reviewed alzhub usefulness score 58 out of 100. The Journal of clinical endocrinology and metabolism 2006-04-24

In our study, TSH was related neither to risk of AD nor with early MRI markers thereof, arguing against an important role of thyroid function in the development of AD. 4 key findings →

Design: cohort study Participants: 1,025 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Extent and distribution of white matter hyperintensities in normal aging, MCI, and AD

✓ Peer-reviewed alzhub usefulness score 56 out of 100. Neurology 2006-12-01

Differences in white matter hyperintensities (WMH) associated with increasing cognitive impairment appear related to both extent and spatial location. 5 key findings →

Design: post-hoc analysis Participants: 26 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Hypoperfusion in frontotemporal dementia and Alzheimer disease by arterial spin labeling MRI

✓ Peer-reviewed alzhub usefulness score 56 out of 100. Neurology 2006-10-01

Frontotemporal dementia and Alzheimer disease display different spatial distributions of hypoperfusion on arterial spin labeling MRI. 2 key findings →

Design: cross-sectional Participants: 21 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Use of hippocampal and amygdalar volumes on magnetic resonance imaging to predict dementia in cognitively intact elderly people

✓ Peer-reviewed alzhub usefulness score 56 out of 100. Archives of general psychiatry 2006-01-01

Atrophy of the hippocampus and amygdala on MRI in cognitively intact elderly people predicts dementia during a 6-year follow-up. 5 key findings →

Design: cohort study Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Loss of expectation-related mechanisms in Alzheimer's disease makes analgesic therapies less effective

✓ Peer-reviewed alzhub usefulness score 55 out of 100. Pain 2006-02-10

Expectation/placebo-related mechanisms and specific effects of therapies show additive effects, such that a therapy is less effective if the placebo component is absent. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Cerebral microbleeds on MRI: prevalence, associations, and potential clinical implications

✓ Peer-reviewed alzhub usefulness score 54 out of 100. Neurology 2006-01-01

Cerebral microbleeds might indicate a higher risk of future intracerebral hemorrhage and may be a marker of cerebral small-vessel disease and cerebral amyloid angiopathy. 4 key findings →

Participants: 5,200 Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

The contribution of voxel-based morphometry in staging patients with mild cognitive impairment

✓ Peer-reviewed alzhub usefulness score 54 out of 100. Neurology 2006-08-01

Different patterns of gray matter density distribution in patients with mild cognitive impairment may be associated to different rates of conversion to Alzheimer disease. 3 key findings →

Participants: 22 Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Magnetoencephalographic evaluation of resting-state functional connectivity in Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 50 out of 100. NeuroImage 2006-07-11

Statistical interdependencies between magnetoencephalographic signals recorded over different brain regions may reflect the functional connectivity of the resting-state networks. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Magnetic resonance imaging of iron deposition in neurological disorders

✓ Peer-reviewed alzhub usefulness score 50 out of 100. Topics in magnetic resonance imaging : TMRI 2006-02-01

Deposition of iron in the brain is proposed to play a role in the pathophysiology of the normal aging process and neurodegenerative diseases. 2 key findings →

Design: longitudinal study Evidence: moderate

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Heterogeneity of ubiquitin pathology in frontotemporal lobar degeneration: classification and relation to clinical phenotype

✓ Peer-reviewed alzhub usefulness score 50 out of 100. Acta neuropathologica 2006-09-26

We have investigated the extent and pattern of immunostaining for ubiquitin protein (UBQ) in 60 patients with frontotemporal lobar degeneration (FTLD) with ubiquitin-positive, tau-negative inclusions (FTLD-U), 37 of whom were ascertained in Manchester UK and 23 in Newcastle-Upon-Tyne, UK. 1 key finding →

Participants: 60 Evidence: low

Full summary, score breakdown and related studies → Original source

Differential regional atrophy of the cingulate gyrus in Alzheimer disease: a volumetric MRI study

✓ Peer-reviewed alzhub usefulness score 48 out of 100. Cerebral cortex (New York, N.Y. : 1991) 2006-01-04

Magnetic resonance imaging-based volumetric measurements provide a useful technique for quantifying in vivo regional cerebral atrophy in Alzheimer disease (AD). 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Relationship between cognitive impairment and retinal morphological and visual functional abnormalities in Alzheimer disease

✓ Peer-reviewed alzhub usefulness score 43 out of 100. Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society 2006-03-01

Our study confirms some other studies in showing that in AD patients there is a reduction of parapapillary and macular RNFL thickness and macular volume as measured by OCT. 5 key findings →

Participants: 14 Evidence: low

Full summary, score breakdown and related studies → Original source

Differences between Alzheimer's disease and dementia with Lewy bodies: an fMRI study of task-related brain activity

✓ Peer-reviewed alzhub usefulness score 42 out of 100. Brain : a journal of neurology 2006-05-02

We investigated whether previously reported differences between Alzheimer's disease and dementia with Lewy bodies (DLB) in resting occipital activity lead to activation differences within functionally specialized visual cortical areas and deactivation differences in the default network. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed